Table 1.
Baseline characteristics of patients enrolled in the cohort “panitumumab for patients with RAF/RASwt recurrent glioblastoma.”
| Characteristics | No. of patients (%) |
|---|---|
| Median age, years (range) | 54.5 (35-73) |
| Gender | |
| Male | 19 (70%) |
| Female | 8 (30%) |
| WHO performance status | |
| WHO 0 | 6 (22%) |
| WHO 1 | 18 (67%) |
| WHO 2 | 1 (4%) |
| Unknown | 2 (7%) |
| Prior lines of systemic therapy after SoC (“temozolomide/radiotherapy”) 2 | |
| 0 | 16 (59%) |
| 1 | 8 (30%) |
| 2 | 3 (11%) |
| WHO classification 23 | |
| IDHwt glioblastoma | 23 (85%) |
| IDH mutant, grade 3 astrocytoma | 2 (7.5%) |
| IDH mutant, grade 4 astrocytoma | 2 (7.5%) |
| Median time from first diagnosis to start study treatment, months (range) | 14 (5-197) |
| Prognostic factors | |
| 1.MGMT promoter methylation | |
| Yes | 3 (11%) |
| No | 14 (52%) |
| Unknown | 10 (37%) |
| 2. IDH1/2 mutation | |
| Yes | 4 (15%) |
| No | 23 (85%) |
Abbreviations: NO, number; WHO, World Health Organization; SoC, Standard of Care